Delving into the Latest Updates on Inactivated whole virus influenza vaccine(KM Biologics KK) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine

Synonyms

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza, Human

Inactive Indication-

Originator Organization

KM Biologics KK

Active Organization

Hokkaido UniversityMeiji Seika Kaisha Ltd.

KM Biologics KK

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Author: Kruglov, Andrey A ; Ustyugov, Aleksey A ; Gogoleva, Violetta S ; Drutskaya, Marina S ; Lunin, Aleksandr S ; Zvartsev, Ruslan ; Shustova, Elena Yu ; Ishmukhametov, Aydar A ; Nedospasov, Sergei A ; Semin, Iaroslav K ; Apolokhov, Vasiliy D ; Astrakhantseva, Irina V ; Kozlovskaya, Liubov I ; Volok, Viktor P ; Bondareva, Marina A

AbstractCOVID‐19 is a systemic inflammatory disease initiated by SARS‐CoV‐2 virus infection. Multiple vaccines against the Wuhan variant of SARS‐CoV‐2 have been developed including a whole virion beta‐propiolactone‐inactivated vaccine based on the B.1.1 strain (CoviVac). Since most of the population has been vaccinated by targeting the original or early variants of SARS‐CoV‐2, the emergence of novel mutant variants raises concern over possible evasion of vaccine‐induced immune responses. Here, we report on the mechanism of protection by CoviVac, a whole virion‐based vaccine, against the Omicron variant. CoviVac‐immunized K18‐hACE2 Tg mice were protected against both prototype B.1.1 and BA.1‐like (Omicron) variants. Subsequently, vaccinated K18‐hACE2 Tg mice rapidly cleared the infection via cross‐reactive T‐cell responses and cross‐reactive, non‐neutralizing antibodies recognizing the Omicron variant Spike protein. Thus, our data indicate that efficient protection from SARS‐CoV‐2 variants can be achieved by the orchestrated action of cross‐reactive T cells and non‐neutralizing antibodies.

01 Jan 2023·Frontiers in immunology

Prolonging the delivery of influenza virus vaccine improves the quantity and quality of the induced immune responses in mice.

Article

Author: de Vries-Idema, Jacqueline J ; Beukema, Martin ; Krammer, Florian ; Huckriede, Anke ; Zhou, Fan ; Cox, Rebecca Jane ; Al-Jaawni, Kasem ; Gong, Shuran

IntroductionInfluenza vaccines play a vital role in protecting individuals from influenza virus infection and severe illness. However, current influenza vaccines have suboptimal efficacy, which is further reduced in cases where the vaccine strains do not match the circulating strains. One strategy to enhance the efficacy of influenza vaccines is by extended antigen delivery, thereby mimicking the antigen kinetics of a natural infection. Prolonging antigen availability was shown to quantitatively enhance influenza virus-specific immune responses but how it affects the quality of the induced immune response is unknown. Therefore, the current study aimed to investigate whether prolongation of the delivery of influenza vaccine improves the quality of the induced immune responses over that induced by prime-boost immunization.MethodsMice were given daily doses of whole inactivated influenza virus vaccine for periods of 14, 21, or 28 days; the control group received prime-boost immunization with a 28 days interval.ResultsOur data show that the highest levels of cellular and humoral immune responses were induced by 28 days of extended antigen delivery, followed by 21, and 14 days of delivery, and prime-boost immunization. Moreover, prolonging vaccine delivery also improved the quality of the induced antibody response, as indicated by higher level of high avidity antibodies, a balanced IgG subclass profile, and a higher level of cross-reactive antibodies.ConclusionsOur findings contribute to a better understanding of the immune response to influenza vaccination and have important implications for the design and development of future slow-release influenza vaccines.

01 Oct 2022·Emerging Infectious Diseases

Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru

Review

Author: Silva, Maria ; Espinoza, Angelica ; Bollinger, Susan ; Lessa, Fernanda C. ; Prouty, Michael ; Azziz-Baumgartner, Eduardo ; Olson, Natalie ; Westercamp, Matthew ; Smith, Rachel ; Romero, Candice ; Matos, Eduardo ; Arriola, Carmen S. ; Grogl, Max ; Llanos-Cuentas, Alejandro ; Soto, Giselle

In February 2021, Peru launched a COVID-19 vaccination campaign among healthcare personnel using an inactivated whole-virus vaccine. The manufacturer recommended 2 vaccine doses 21 days apart. We evaluated vaccine effectiveness among an existing multiyear influenza vaccine cohort at 2 hospitals in Lima. We analyzed data on 290 participants followed during February-May 2021. Participants completed a baseline questionnaire and provided weekly self-collected nasal swab samples; samples were tested by real-time reverse transcription PCR. Median participant follow-up was 2 (range 1-11) weeks. We performed multivariable logistic regression and adjusted for preselected characteristics. During the study, 25 (9%) participants tested SARS-CoV-2-positive. We estimated adjusted vaccine effectiveness at 95% (95% CI 70%-99%) among fully vaccinated participants and 100% (95% CI 88%-100%) among partially vaccinated participants. These data can inform the use and acceptance of inactivated whole-virus vaccine and support vaccination efforts in the region.

100 Deals associated with Inactivated whole virus influenza vaccine(KM Biologics KK)

Login to view more data